Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 3/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237633 | 0.92 | CA1 (0.37) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL4764842 | 0.84 | ALDH1A1 (0.38) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL10128627 | 0.83 | ALDH1A1 (0.37) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL12461232 | 0.81 | CYP4F2 (0.37) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL25398102 | 0.80 | MLYCD (0.41) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL12461336 | 0.79 | CYP4F2 (0.36) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL25061570 | 0.79 | ALDH1A1 (0.35) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL24517870 | 0.79 | PPM1B (0.36) | CA1CA2ALDH1A1MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL25399110 | 0.78 | CYP4F2 (0.35) | CA1CA2ALDH1A1MAPTMEN1 | |
| SCHEMBL24518104 | 0.75 | THRB (0.38) | ALDH1A1MAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116912-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4271377-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Terns Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116887827-A | Compounds and methods for modulating FXR | 拓臻制药公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2022147448-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | TERNS PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-9168248-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2015-10-27 | — | — | US | disclosed |
| EP-2398809-B1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2015-07-08 | — | — | EP | disclosed |
| US-8383643-B2 | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase | MERCK CANADA INC. (CA) | 2013-02-26 | — | — | US | disclosed |
| EP-2459568-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Limited (CA) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| EP-2099793-B1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8063224-B2 | [5-(5-{4-[2-(Trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)-2H-tetrazol-2-yl]acetic acid; metabolic disorders,antidiabetic, hypoglycemic agent; obesity, insulin resistance, liver steatosis, atherosclerosis, neurological disease, dyslipidemia, hyperlipidemia, low HDL, and high LDL | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| WO-2011011872-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010108268-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108268-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010094120-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| EP-2099793-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064474-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122912-A1 | NOVEL SPIRO COMPOUNDS USEFUL AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | CA1 4460/4885CA2 4225/4885ALDH1A1 300/4885 |
| US-20240116912-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, FXR2 | CA1 3363/4885CA2 4200/4885ALDH1A1 2259/4885 |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | CA1 4569/4885CA2 4504/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.